What is HC Wainwright’s Forecast for MNPR FY2026 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at HC Wainwright increased their FY2026 EPS estimates for Monopar Therapeutics in a research note issued on Wednesday, January 22nd. HC Wainwright analyst S. Lee now anticipates that the company will earn $0.70 per share for the year, up from their previous forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2027 earnings at $2.10 EPS and FY2028 earnings at $3.04 EPS.

Other research analysts also recently issued reports about the stock. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $50.00 target price on the stock. Piper Sandler assumed coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $72.00 price target on the stock.

Monopar Therapeutics Stock Performance

Shares of MNPR opened at $41.46 on Friday. The firm has a market cap of $252.91 million, a price-to-earnings ratio of -21.05 and a beta of 1.23. Monopar Therapeutics has a fifty-two week low of $1.54 and a fifty-two week high of $41.94. The firm has a 50 day moving average price of $24.65 and a 200-day moving average price of $12.60.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Insider Buying and Selling

In related news, CFO Karthik Radhakrishnan acquired 1,550 shares of Monopar Therapeutics stock in a transaction dated Monday, October 28th. The shares were purchased at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at approximately $25,187.50. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 34.90% of the stock is currently owned by insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.